AT92107T - N-terminal fragments of human serum albumin-containing fusion proteins. - Google Patents

N-terminal fragments of human serum albumin-containing fusion proteins.

Info

Publication number
AT92107T
AT92107T AT90304575T AT90304575T AT92107T AT 92107 T AT92107 T AT 92107T AT 90304575 T AT90304575 T AT 90304575T AT 90304575 T AT90304575 T AT 90304575T AT 92107 T AT92107 T AT 92107T
Authority
AT
Austria
Prior art keywords
fusion proteins
serum albumin
human serum
terminal fragments
containing fusion
Prior art date
Application number
AT90304575T
Other languages
German (de)
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Priority to GB898909919A priority Critical patent/GB8909919D0/en
Priority to EP90304575A priority patent/EP0399666B1/en
Publication of AT92107T publication Critical patent/AT92107T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
AT90304575T 1989-04-29 1989-04-26 N-terminal fragments of human serum albumin-containing fusion proteins. AT92107T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB898909919A GB8909919D0 (en) 1989-04-29 1989-04-29 Small polypeptides
EP90304575A EP0399666B1 (en) 1989-04-29 1990-04-26 Fusion proteins containing n-terminal fragments of human serum albumin

Publications (1)

Publication Number Publication Date
AT92107T true AT92107T (en) 1993-08-15

Family

ID=10656003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90304575T AT92107T (en) 1989-04-29 1989-04-26 N-terminal fragments of human serum albumin-containing fusion proteins.

Country Status (7)

Country Link
EP (2) EP0399666B1 (en)
AT (1) AT92107T (en)
DE (2) DE69002395D1 (en)
DK (1) DK0399666T3 (en)
ES (1) ES2060033T3 (en)
GB (1) GB8909919D0 (en)
WO (1) WO1990013306A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE69012950T2 (en) * 1989-10-13 1995-03-16 Takara Shuzo Co Anticancer agents.
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical compositions containing them.
FR2719593B1 (en) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical composition containing them.
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
JP3192067B2 (en) * 1995-10-09 2001-07-23 科学技術振興事業団 Peptides and collagen contraction inhibitor
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2236152B1 (en) 2000-04-12 2014-06-04 Novozymes Biopharma DK A/S Albumin fusion proteins
AU8668801A (en) * 2000-08-25 2002-03-13 Human Genome Sciences Inc Tumor necrosis factor receptors 6alpha and 6beta
CN101712722A (en) 2000-12-07 2010-05-26 伊莱利利公司 Glp-1 fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
CN101724071A (en) 2004-10-08 2010-06-09 杜门蒂斯有限公司 Single domain antibodies against TNFRl and methods of use therefor
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP5401095B2 (en) 2005-11-17 2014-01-29 ゾゲニクス インコーポレーティッド Delivery method of viscous preparation by needle-free injection
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EA200901494A1 (en) 2007-06-06 2010-06-30 Домантис Лимитед Methods of selection of proteaso-resistant polypeptides
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
BRPI0921586A2 (en) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc human serum albumin articulators and conjugates thereof
ES2563061T3 (en) 2008-04-28 2016-03-10 Zogenix, Inc. New formulations for the treatment of migraine
CA2723277A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
PL2318029T3 (en) 2008-07-23 2018-03-30 Elanco Us Inc. Modified bovine g-csf polypeptides and their uses
KR101740066B1 (en) 2008-12-05 2017-05-25 글락소 그룹 리미티드 Methods for selecting protease resistant polypeptides
BRPI1008014A2 (en) 2009-02-19 2016-10-04 Glaxo Group Ltd simple variable domain, multispecific ligand, tnfr1, and tnf-alpha receptor antagonists, use of tnfr agonist, anti-tnfr1 antagonist, polypeptide or multispecific ligand, method for treating and / or preventing a condition or disease, nucleic acid, vector and host
WO2011006914A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
KR20120101417A (en) 2009-10-27 2012-09-13 글락소 그룹 리미티드 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
KR20130066632A (en) 2010-05-06 2013-06-20 노파르티스 아게 Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
PT2605789T (en) 2010-08-17 2019-09-03 Ambrx Inc Modified relaxin polypeptides and their uses
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
BR112014000055A2 (en) 2011-07-01 2017-06-13 Bayer Ip Gmbh relaxin fusion polypeptides and uses thereof
CA2840944A1 (en) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
KR20140091031A (en) 2011-11-04 2014-07-18 노파르티스 아게 Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
MX362521B (en) 2011-12-05 2019-01-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3).
CA2857601A1 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN107739409A (en) 2012-05-18 2018-02-27 爱德迪安(北京)生物技术有限公司 Albumen, protein conjugate and its application for treating diabetes
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
US20190367628A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
SE459586B (en) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Structural gene coding foer authentic human serum albumin and its foerfarande foer framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
AU2719088A (en) * 1987-11-09 1989-06-01 Chiron Ophthalmics Inc. Wound healing composition and method

Also Published As

Publication number Publication date
EP0407008A3 (en) 1991-07-17
WO1990013306A2 (en) 1990-11-15
GB8909919D0 (en) 1989-06-14
DE69002395T2 (en) 1993-11-25
EP0407008A2 (en) 1991-01-09
WO1990013306A3 (en) 1991-05-02
EP0399666A1 (en) 1990-11-28
ES2060033T3 (en) 1994-11-16
DE69002395D1 (en) 1993-09-02
DK0399666T3 (en) 1993-08-30
EP0399666B1 (en) 1993-07-28

Similar Documents

Publication Publication Date Title
GB2246783B (en) Fusion proteins containing n-terminal fragments of human serum albumin
AT57836T (en) Undenatured virus-free biologically active protein derivatives.
DK0557350T3 (en) Assay for glycated blood proteins
DE69014162D1 (en) Bone morphogenetic protein.
DE741187T1 (en) Recombinant Obesitäts- (OB) proteins
NO890029D0 (en) Novel modified peptides and proteins for in vitro diagnoses (diabetes).
DE3853918T2 (en) Biologically active bactericidal / durchlässigkeitserhöhende protein fragments.
DE68928321D1 (en) anti-aggregative peptides
DE69017751T2 (en) Labeled chemotactic peptides for visualization of inflammation and infection sites.
DE10075024I1 (en) peptides
DE69018226T2 (en) Labeled polypeptide derivatives.
FI20022285A (en) The isolated CTL4A soluble protein, containing the fusion proteins, the ligands to recognizing monoclonal antibodies, and uses
DE69007055T2 (en) Pancreatin preparations.
DE3588058T2 (en) Polypeptides inducing factors in bone and cartilage.
NO922237D0 (en) Proteins and nucleic acids
DK0460171T3 (en) CD3-specific recombinant antibody
DE3752253T2 (en) Recombinant Alzheimer amyloid protein.
DK72593D0 (en) recombinant protein
DE3854555T2 (en) Expression of proteins in milk.
AT178908T (en) Lys (B28) insulins. analog of the human insulins
DE68914835D1 (en) Protein products.
NO902082L (en) Fibronectin binding protein as well as the preparation thereof.
DE69322645T2 (en) Expression of recombinant fusion proteins in attenuated bacteria
AT73138T (en) Cleaning and proteins inclusion activation of insoluble.
DE59010908D1 (en) TNF-binding proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time